USA-patented, FDA-cleared pain gadget released in city

January 04, 2016 12:00 am | Updated September 22, 2016 09:52 pm IST - VIJAYAWADA:

US-based neurologist M. Krishna Kant (right) demonstrating the Chronic Pain Relief gadget on Andhra Hospitals CEO P V Ramana Murthy, in Vijayawada on Sunday.- Photo: Ch. Vijaya Bhaskar

US-based neurologist M. Krishna Kant (right) demonstrating the Chronic Pain Relief gadget on Andhra Hospitals CEO P V Ramana Murthy, in Vijayawada on Sunday.- Photo: Ch. Vijaya Bhaskar

A US-patented, FDA-cleared gadget that gives relief to chronic pain was released in Andhra Pradesh here on Sunday.

Andhra group of hospitals CEO P.V. Ramana Murthy releasing the Chronic Pain Relief Wand, marketed by Ritwik Pharma, at the Indian Medical Association (IMA) Hall said that it was a matter of pride for the Telugus that a team led by US based Telugu doctor, neurologist and sleep medicine specialist M. Krishna Kant could get FDA clearance and patent rights for the pain relief gadget.

He said only the very best medicines and gadgets usually get FDA clearance. Dr. Krishna Kant said that the invention of the pain relief gadget was need driven because of the lack of effective treatment options for chronic pain. He said the medical devise was powerful enough to relieve moderate to severe pain within minutes in a non-pharmaceutical and non invasive manner.

The product was world class ergonomically designed without the hassles of wires, electrodes and patches and no maintenance cost.

He said that the gadget was being first released in the Telugu states and subsequently in others.

IMA Vijayawada chapter president P.M.C. Naidu, Secretary Ravindranath were present at the release function. While the pain relief wand was priced 500 dollars (Rs.33,000) in the United States it had been priced at Rs.20,000 in India. The price was on the higher side because of the new technology involved but was being discounted in India Dr. Kant said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.